<DOC>
	<DOCNO>NCT00402077</DOCNO>
	<brief_summary>This study examine safety , tolerability , body weight effect subcutaneous pramlintide alone various combination oral antiobesity agent sibutramine phentermine overweight obese subject .</brief_summary>
	<brief_title>A Study Examine Safety , Tolerability , Body Weight Effect Pramlintide Alone Combination With Oral Antiobesity Agents Overweight Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<mesh_term>Anti-Obesity Agents</mesh_term>
	<criteria>Is obese Body Mass Index ( BMI ) &gt; =30 kg/m^2 &lt; =50 kg/m^2 overweight BMI &gt; =27 kg/m^2 presence risk factor ( e.g. , hyperlipidemia , sleep apnea , treatment condition ) Has obese overweight least one year prior study start Either treat stable treatment regimen follow medication minimum 2 month prior study start : *hormone replacement therapy ; *oral contraceptive ; *lipidlowering agent ; *thyroid replacement therapy ; *metformin Is currently enrol planning enroll formal weightloss program Is unwilling unable participate lifestyle intervention program part study Has treat ( within 2 month prior study start ) , currently treat , expect require undergo treatment follow excluded medication : *prescription counter antiobesity agent ( within 6 month prior study start ) ; *psychotropic/neurological agent ( i.e. , antipsychotic , antiepileptic , antidepressant , antianxiety agent , mood stabilizer ) ; *steroids know result high systemic absorption ; *calcitonin ; *ketoconazole ; *antidiabetic medication Has liposuction , abdominoplasty , similar procedure within 1 year study start plan procedure study Has receive investigational drug within 1 month ( 5 halflives investigational drug , whichever great ) study start Has previously use pramlintide either prescription part clinical study Has use sibutramine phentermine ( either prescription part clinical study ) within 2 year study start Has donate blood within 2 month study start , plan donate blood study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
	<keyword>sibutramine</keyword>
	<keyword>Meridia</keyword>
	<keyword>phentermine</keyword>
	<keyword>Amylin</keyword>
</DOC>